pyrazolanthrone has been researched along with Lymphoma, Large B-Cell, Diffuse in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Claret, FX; Drakos, E; Elenitoba-Johnson, KS; Leventaki, V; Lim, MS; Medeiros, LJ; Rassidakis, GZ | 1 |
1 other study(ies) available for pyrazolanthrone and Lymphoma, Large B-Cell, Diffuse
| Article | Year |
|---|---|
NPM-ALK oncogenic kinase promotes cell-cycle progression through activation of JNK/cJun signaling in anaplastic large-cell lymphoma.
Topics: Anthracenes; Cell Cycle; Cell Transformation, Neoplastic; Chromosomes, Human, Pair 2; Chromosomes, Human, Pair 5; Cyclin A; Cyclin D3; Cyclins; Dose-Response Relationship, Drug; Down-Regulation; Enzyme Activation; Humans; Jurkat Cells; Lymphoma, Large B-Cell, Diffuse; Mitogen-Activated Protein Kinase 8; Mitogen-Activated Protein Kinase 9; Oncogene Proteins, Fusion; p21-Activated Kinases; Phosphorylation; Protein Serine-Threonine Kinases; Protein-Tyrosine Kinases; Signal Transduction; Transcription Factor AP-1; Transcription, Genetic; Translocation, Genetic; Up-Regulation | 2007 |